Trial Profile
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% ophthalmic solution
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2021
Price :
$35
*
At a glance
- Drugs Carteolol/latanoprost (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions; Therapeutic Use
- 24 Feb 2021 Status changed from recruiting to completed.
- 24 Aug 2020 According to UMIN record data analysis concluded on 18 Apr 2020.
- 22 Feb 2017 New trial record